Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABCL with free AI briefings, catalyst countdowns, and dilution alerts.

ABCL · AbCellera Biologics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$764.4M Cash on Hand
CF+ Cash Runway
Follow ABCL by email Get an email when ABCL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABCL, unsubscribe in one click. Privacy

📣 What ABCL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bamlanivimab (LY3819253) COVID-19 Phase 3 · NCT04497987 Completed
Etesevimab COVID-19 Phase 3 · NCT04497987 Completed
Bebtelovimab (LY3853113) COVID-19 Phase 2/3 · NCT04427501 Completed
ABCL635 Vasomotor Symptoms Associated With Menopause Phase 1/2 · NCT07118891 Active not recruiting
Sotrovimab (VIR-7831) COVID-19 Phase 2 · NCT04634409 Completed
ABCL575 Healthy Volunteers Phase 1 · NCT07108894 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABCL holds $764.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABCL files for a raise →

👥 Who Owns ABCL

Insiders 39.2% Institutions (192 holders) 36.8% Public and other holders 24%
HolderTypeShares% of sharesAs of
Carl L. G. Hansen
Chief Executive Officer, Director, 10% o · +32.35M options
Insider 65,913,149 20.18% 2026-09-30
Thermopylae Holdings Ltd.
10% owner
Insider 56,069,662 17.17% 2026-11-13
Baker Bros. Advisors LP Institution (13G, 5%+) 33,012,138 10.11% 2026-04-30
Veronique Lecault
Chief Technology Officer, Director · +13.69M options
Insider 2,458,666 0.75% 2024-06-21
Michael R Hayden
Director · +1.91M options
Insider 1,491,642 0.46% 2026-08-24
Stephen Quake
Director · +501,565 options
Insider 1,100,436 0.34% 2025-11-10
Andrew Booth
Chief Financial Officer · +25.15M options
Insider 622,359 0.19% 2026-11-13
John S. Montalbano
Director · +2.17M options
Insider 256,000 0.08% 2026-08-18

Share count 326,617,896 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABCL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABCL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.